All public logs
Jump to navigation
Jump to search
Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 01:53, 8 May 2024 Edzelco talk contribs created page File:LOQTORZI Dosage.png
- 01:53, 8 May 2024 Edzelco talk contribs uploaded File:LOQTORZI Dosage.png
- 08:08, 17 April 2024 Edzelco talk contribs created page Elranatamab-bcmm (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:08, 17 April 2024 Edzelco talk contribs created page Palovarotene (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:08, 17 April 2024 Edzelco talk contribs created page Pozelimab-bbfg (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:07, 17 April 2024 Edzelco talk contribs created page Motixafortide (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:07, 17 April 2024 Edzelco talk contribs created page Momelotinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:06, 17 April 2024 Edzelco talk contribs created page Cipaglucosidase alfa-atga (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:05, 17 April 2024 Edzelco talk contribs created page Etrasimod (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:05, 17 April 2024 Edzelco talk contribs created page Zilucoplan (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Edzelco talk contribs created page Bimekizumab (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Edzelco talk contribs created page Vamorolone (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Edzelco talk contribs created page Mirikizumab-mrkz (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:03, 17 April 2024 Edzelco talk contribs created page Toripalimab-tpzi (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:02, 17 April 2024 Edzelco talk contribs created page Fruquintinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...")
- 07:52, 17 April 2024 Edzelco talk contribs created page Taurolidine, heparin (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...")
- 07:43, 17 April 2024 Edzelco talk contribs created page Repotrectinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru...")
- 07:32, 17 April 2024 Edzelco talk contribs created page Efbemalenograstim alfa-vuxw (Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle....")
- 05:50, 16 April 2024 Edzelco talk contribs created page Capivasertib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based...")
- 05:27, 16 April 2024 Edzelco talk contribs created page Iptacopan (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me...")
- 07:24, 15 April 2024 Edzelco talk contribs created page Vutrisiran (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=vutrisiran |aOrAn=a |drugClass=transthyretin-directed small interfering RNA |indicationType=treatment |indication=polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=pain in extremity, arthralgia, dyspnea, and decreased vitamin A levels. |fdaLIADAdult=Recommended Dosage The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous inj...")
- 22:23, 11 February 2024 Edzelco talk contribs created page Mavacamten (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mavacamten |aOrAn=a |drugClass=cardiac myosin inhibitor |indicationType=treatment |indication=adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms |hasBlackBoxWarning=Yes |adverseReactions=dizziness (27%) and syncope (6%) |blackBoxWarningTitle=WARNING: RISK OF HEART...")
- 19:04, 10 February 2024 Edzelco talk contribs created page Oteseconazole (Created page with "{{DrugProjectFormSinglePage |genericName=oteseconazole |aOrAn=an |drugClass=azole antifungal |indicationType=prevention |indication=recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential |adverseReactions=headache and nausea |fdaLIADAdult=VIVJOA Capsules: 150 mg of oteseconazole in lavender hard gelatin capsules imprinted with OTE 150 in black ink. Fluconazole is not supplied in the carton. |co...")
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label3.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label3.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label2.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label2.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA structure.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA structure.png
- 00:47, 7 February 2024 Edzelco talk contribs created page Lutetium (177Lu) vipivotide tetraxetan (Created page with "{{DrugProjectFormSinglePage |genericName=lutetium (177Lu) vipivotide tetraxetan |aOrAn=a |drugClass=radioligand therapeutic agent |indicationType=treatment |indication=adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy |adverseReactions=fatigue, dry mout...")
- 00:44, 7 February 2024 Edzelco talk contribs created page File:Pluvicto label.png
- 00:44, 7 February 2024 Edzelco talk contribs uploaded File:Pluvicto label.png
- 00:44, 7 February 2024 Edzelco talk contribs created page File:Pluvicto structure.png
- 00:44, 7 February 2024 Edzelco talk contribs uploaded File:Pluvicto structure.png
- 00:57, 6 February 2024 Edzelco talk contribs created page Nivolumab and relatlimab-rmbw (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=nivolumab and relatlimab-rmbw |aOrAn=a |drugClass=combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody |indicationType=treatment |indication=adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma |adverseReactions=immune-mediated pneumonitis, im...")
- 00:56, 6 February 2024 Edzelco talk contribs created page File:Nivolumab and relatlimab-rmbw label.png
- 00:56, 6 February 2024 Edzelco talk contribs uploaded File:Nivolumab and relatlimab-rmbw label.png
- 00:22, 6 February 2024 Edzelco talk contribs created page File:Ganaloxone bottle carton.png
- 00:22, 6 February 2024 Edzelco talk contribs uploaded File:Ganaloxone bottle carton.png
- 00:22, 6 February 2024 Edzelco talk contribs created page File:Ganaloxone bottle suspension label 50mg.png
- 00:22, 6 February 2024 Edzelco talk contribs uploaded File:Ganaloxone bottle suspension label 50mg.png
- 00:21, 6 February 2024 Edzelco talk contribs created page File:Ganaloxone structure.png
- 00:21, 6 February 2024 Edzelco talk contribs uploaded File:Ganaloxone structure.png
- 15:47, 2 February 2024 Edzelco talk contribs created page Pacritinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Pacritinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L (1) |adverseReactions=diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema |fdaLIADAdult=The recommended dosage of VONJO is 200 mg orally twi...")
- 15:47, 2 February 2024 Edzelco talk contribs created page File:Pacritinib Bottle Label.png
- 15:47, 2 February 2024 Edzelco talk contribs uploaded File:Pacritinib Bottle Label.png
- 15:47, 2 February 2024 Edzelco talk contribs created page File:Pacritinib Carton Label.png
- 15:47, 2 February 2024 Edzelco talk contribs uploaded File:Pacritinib Carton Label.png
- 15:47, 2 February 2024 Edzelco talk contribs created page File:Pacritinib supply.png
- 15:47, 2 February 2024 Edzelco talk contribs uploaded File:Pacritinib supply.png
- 15:47, 2 February 2024 Edzelco talk contribs created page File:Pacritinib structure.png
- 15:47, 2 February 2024 Edzelco talk contribs uploaded File:Pacritinib structure.png
- 16:13, 1 February 2024 Edzelco talk contribs created page Mitapivat (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mitapivat |aOrAn=a |drugClass=pyruvate kinase activator |indicationType=treatment |indication=hemolytic anemia in adults with pyruvate kinase (PK) deficiency |adverseReactions=estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia |fdaLIADAdult=PYRUKYND is taken with or without food and swallowed whole. Do not split, crush, chew,...")
- 16:08, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 5mg.png
- 16:08, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 5mg.png
- 16:08, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 5mg tablet blister pack.png
- 16:08, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 5mg tablet blister pack.png
- 16:07, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 20mg.png
- 16:07, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 20mg.png
- 16:07, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 20mg tablet blister pack.png
- 16:07, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 20mg tablet blister pack.png
- 16:07, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 50mg.png
- 16:07, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 50mg.png
- 16:07, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 50mg tablet blister pack.png
- 16:07, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 50mg tablet blister pack.png
- 16:06, 1 February 2024 Edzelco talk contribs created page File:Mitapivat structure.png
- 16:06, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat structure.png
- 16:06, 1 February 2024 Edzelco talk contribs created page File:Mitapivat supply.png
- 16:06, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat supply.png
- 15:46, 1 February 2024 Edzelco talk contribs created page Sutimlimab-jome (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Sutimlimab-jome |aOrAn=a |drugClass=classical complement inhibitor |indicationType=treatment |indication=hemolysis in adults with cold agglutinin disease (CAD) |adverseReactions=in the CADENZA study (Part A) (incidence ≥18%) are rhinitis, headache, hypertension, acrocyanosis, and Raynaud's phenomenon. The most common adverse reactions in the CARDINAL study (incidence ≥...")
- 15:44, 1 February 2024 Edzelco talk contribs created page File:Sutimlimab-jome packaging.png
- 15:44, 1 February 2024 Edzelco talk contribs uploaded File:Sutimlimab-jome packaging.png
- 15:31, 1 February 2024 Edzelco talk contribs created page Faricimab-svoa (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Faricimab-svoa |aOrAn=a |drugClass=vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor |indicationType=treatment |indication=patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO) |adverseReactions=cataract (15%) and [[conjunctival hemorrhage]...")
- 14:59, 1 February 2024 Edzelco talk contribs created page Tebentafusp-tebn (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Tebentafusp-tebn |aOrAn=a |drugClass=bispecific gp100 peptide-HLA-directed CD3 T cell engager |indicationType=treatment |indication=HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma |hasBlackBoxWarning=Yes |adverseReactions=cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache and vomiting. The most...")
- 01:46, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib 200mg.png
- 01:46, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib 200mg.png
- 01:46, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib 100mg.png
- 01:46, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib 100mg.png
- 01:43, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib 50mg.png
- 01:43, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib 50mg.png
- 01:39, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib supply.png
- 01:39, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib supply.png
- 01:32, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib.png
- 01:32, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib.png
- 01:31, 1 February 2024 Edzelco talk contribs created page Abrocitinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |indicationType=treatment |indication=adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOS...")
- 21:17, 31 January 2024 Edzelco talk contribs created page Daridorexant (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=daridorexant |aOrAn=an |drugClass=orexin receptor antagonist |indicationType=treatment |indication=adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance |adverseReactions=Common adverse reactions (reported in ≥ 5% of patients treated with QUVIVIQ and at an incidence ≥ than placebo) include headache and somnolence or fatigue...")
- 21:15, 31 January 2024 Edzelco talk contribs created page File:Clinical Studies 3.png
- 21:15, 31 January 2024 Edzelco talk contribs uploaded File:Clinical Studies 3.png
- 21:15, 31 January 2024 Edzelco talk contribs created page File:Clinical Studies 2.png
- 21:15, 31 January 2024 Edzelco talk contribs uploaded File:Clinical Studies 2.png
- 21:15, 31 January 2024 Edzelco talk contribs created page File:Clinical Studies 1.png
- 21:15, 31 January 2024 Edzelco talk contribs uploaded File:Clinical Studies 1.png
- 21:07, 31 January 2024 Edzelco talk contribs created page File:Effects of hepatic impairment and renal impairment on daridorexant PK.png
- 21:07, 31 January 2024 Edzelco talk contribs uploaded File:Effects of hepatic impairment and renal impairment on daridorexant PK.png
- 21:07, 31 January 2024 Edzelco talk contribs created page File:Effect of daridorexant on the PK of other compounds.png
- 21:07, 31 January 2024 Edzelco talk contribs uploaded File:Effect of daridorexant on the PK of other compounds.png
- 21:06, 31 January 2024 Edzelco talk contribs created page File:Effect of co-administered compounds on the PK of daridorexant.png
- 21:06, 31 January 2024 Edzelco talk contribs uploaded File:Effect of co-administered compounds on the PK of daridorexant.png